| 产品详情 |
| Edit |   |
|---|
| Product Name | Pranlukast |
|---|
| Description | Purity >97%. The cysteinyl leukotrienes (CysLT) LTC4 and LTD4 are potent mediators of asthma and hypersensitivity. They induce bronchoconstriction, increase microvascular permeability, and are vasoconstrictors of coronary arteries. Their biological effects are transduced by a pair of G protein-coupled receptors, CysLT1 and CysLT2. Pranlukast (ONO-1078) is a potent, selective and orally active cysteinyl leukotriene1 (CysLT1) receptor antagonist. Sold under the trade name Ultair, it was the first cysteinyl (peptidyl) leukotriene receptor antagonist (LTRA) marketed for the treatment of asthma. Clinical studies in Japan, Europe, and North America all show that pranlukast significantly attenuates bronchoconstriction in response to a variety of allergen challenges as well as to inhaled LTD4. Pranlukast binds to the human CysLT1 and CysLT2 receptors with IC50 values of approximately 4-7 nM and 3,600 nM, respectively. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-benzamide, ONO-1078, Ultair |
|---|
| Gene, Accession, CAS # | CAS: 103177-37-3 |
|---|
| Catalog # | LS-H18 |
|---|
| Price | |
|---|
| Order / More Info | Pranlukast from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|